Like this:

These are relative terms. If I license a product from you, I am in-licensing it and you are out-licensing it. If I license a product to you, then I am out-licensing and you are in-licensing. See the full answer at quora

Share this:

Like this:

This is a guest post from Steve Kirsh. Steve is Founder + Managing Partner of Khameleon Group. When was the last time you used a matchmaking service? Chances are it was today. Platforms like Amazon, Airbnb, eBay and Uber (as well as the proverbial dating sites) have transformed matchmaking into an everyday adventure in which […]

Share this:

Like this:

This is a guest post from Avneet Heer, a student in the MS Biotechnology BioBusiness Track at Georgetown University. Do you have a response to Avneet’s post? Respond in the comments section below. Politics, lobbying and monetary incentives have an increasing influence upon patent policy, especially drug patent policy. This has led to concerns over […]

Like this:

How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds? While anecdotal evidence points to some really successful investments (e.g. Abingworth’s investment in Algeta in February 2009 (24x deal return)), this analysis of a large sample of VIPEs in the biotechnology and pharmaceutical industry over […]

Like this:

How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What is the link between first-day return and aftermarket performance? This study examines these questions using a large sample of U.S. venture-backed biotechnology IPOs during 1980 through 2015. The analysis of first-day returns (underpricing) of venture-backed […]